Devil's claw is a common ingredient in nutraceutical products for the treatment of inflammation due to arthritis. The secondary root extract of Harpagophytum procumbens contains bioactive iridoid glycosides known as harpagosides. Recent scrutiny of the nutraceutical industry claims that products listing devil's claw on their labels should refer only to H. procumbens, while the closely related, and less expensive, H. zeyheri is not to be classified as devil's claw. This assertion is in contrast to botanists who claim that either species of Harpagophytum can be generically referred to as devil's claw. The current research aimed to determine the chemical composition of extracts from H. procumbens and H. zeyheri, with the intent to identify whether the bioactive harpagosides were similarly present between species, and how their presence resembled or deviated from commercially available H. procumbens extracts commonly used in nutraceutical products. A microwave extraction followed by high performance liquid chromatography analysis of root samples from botanical specimens of H. procumbens and H. zeyheri identified similar quantities of harpagoside, regardless of species. The chemical composition between root extracts for each species was found to contain varying quantities of non-harpagoside constituents, however their harpagoside content was comparable. These findings are intended to inform policymakers, nutraceutical manufacturers, and the general public of the distinction between myth and reality regarding devil's claw supplements.
Harpagoside is a medicinally valuable iridoid glycoside, which is present in several botanicals including Lamiaceae, Pedaliaceae, Plantaginaceae, Scrophulariaceae, and Rubiaceae families [1] . Harpagoside is a major constituent of Harapgophytum procumbens. The enriched extract of H. procumbens has been used for the treatment of arthritis and other forms of joint pain. Based on the study conducted by Chrubasik et al., a daily dose of at least 50 mg harpagoside is effective for treating arthritis [2] . In a detailed review article, Georgiev et al. [1] reported the medicinal attributes of harpagoside, a few of which are described herein. Enriched extracts containing up to 30% harpagoside are reported to completely inhibit 5-lipoxygenase in vitro. Pure harpagoside and H. procumbens extracts inhibit COX-1/2 expression and nitric oxide production by peritoneal macrophages. Harpagoside suppressed lipo-polysaccharide (LPS)-induced COX-2 and iNOS expression induced in RAW 264.7 cells via the nuclear factor kappa B (NF-κB) signaling pathway. Harpagoside has COX-2 mediated proinflammatory properties [1] . Besides being anti-inflammatory, harpagoside can be used as a treatment for respiratory disorders [3] .
Harpagoside is popularly extracted from H. procumbens, commonly known as devil's claw [4] . The root powders, water and ethanolic extracts have been used in arthritis treatment and dietary supplements. Interestingly, harpagoside can also be extracted from H. zeyheri, a subspecies in the same family. The American, British, and European Pharmacopoeias make provision for the use of either species as long as the harpagoside standard is met in the commercial products (a minimum of 1.2% or more). H. procumbens is comercially preferred because it has been reported to contain higher levels of the biologically active constituents which include harpagoside, harpagide, procumbide and acteosides [5] . Several methods were reported on how to differentiate between the two species. Schmidt et al. noted that 8-p-coumaroylharpagide is present in H. zeyheri in much higher quantities, and that the ratio between the percentage of 8-p-coumaroylharpagide and the sum of harpagoside to 8-p-coumaroylharpagide is a useful quality control measurement to distinguish between the two species. The ratio was reported to be below 10 in H. procumbens and above 31 in H. zeyheri [6] .
Chemical structure of harpagoside Even after the world's major pharmacopeias acceptance of H. zeyheri as a dietary supplement, some policy makers and supplement manufacturers ceased the sale, distribution, and marketing their dietary supplements as they claim their products were adulterated or 'misbranded' as devil's claw with H. zeyheri [7] . However, when concentrated root extracts of the above species are used, both species yield harpagoside quantities that are roughly equivalent. In this work we compared the amount of harpagoside in both H. procumbens and H. zeyheri, with a certified commercial standard of devil's claw extract (more than 3% harpagosides) to show the similarities between the two species of Harpagophytum in bioactive harpagoside content. presence of harpagoside in both H. procumbens and H. zeyheri extracts in approximately equivalent amounts (reference to peak at R T = 16.1 min; i.e. last major peak in each chromatogram). It is also evident that the other chemical constituents of these extracts are present in varying proportions. The significance of these data is that a nutraceutical product claiming to contain devil's claw extract will have similar levels of bioactive harpagoside, regardless of whether the root extract was obtained from H. procumbens or H. zeyheri.
In conclusion, literature precedent has been well established for harpagoside as a bioactive iridoid glycoside that serves as an antiinflammatory agent. It is our finding that the harpagoside content in nutraceutical products should be the basis by which claims of devil's claw can be made and not reliance solely on from which species of Harpagophytum the extract was obtained. Since the harpagoside content in the botanical, even in the same species, can be affected by several factors associated with plant growth and harvest conditions, labeling the nutraceutical products as containing devil's claw and requiring that H. procumbens is the sole species from which extract can be present, does not provide comprehensive information regarding the amount of harpagoside present. Our findings clearly demonstrate that commercial devil's claw extract contains predominately harpagoside, which is a major component of either H. procumbens or H. zeyheri. Measures should be taken by policy makers, manufacturers and distributors to include the total harpagoside content on the nutraceutical labels as this is the therapeutically relevant information for consumers.
Experimental
Plant materials: American herbal pharmacopoeia (AHP) certified botanical reference for dry roots of Harpagophytum procumbens subps. procumbens (Burch.) DC. Ex Meisn. and Harpagophytum zeyheri Decne. were purchased from Alkemist labs (USA). The certificates of authenticity for both materials are provided in supplementary data ( Figure S1 and S2). Commercial devil's claw extract was purchased from BOC Sciences to serve as a harpagoside standard. A certificate of analysis for the devil's claw extract specifying a minimum of 3% harpagosides has been provided in supplementary data ( Figure S3 ).
Microwave assisted extraction:
Each sample (1000 mg) was mixed with 20 mL of distilled water in a 100 mL Ultra Prep Teflon microwave vessel equipped with a stir bar and capped securely. The reaction vessel was heated from room temperature to 120ºC over 4 min in a MARS 5, CEM brand chemical microwave. The temperature was held constant for 10 min using a power of 100 W. A subsequent 10 min cool-down period lowered the solution temperature to below 55ºC. Particulates were removed from the extraction mixture by filtration (0.45 μm) and water was removed by lyophilization. Five mg of the residual material was redissolved in water (1 mL), followed by direct injection into the UPLC.
High performance liquid chromatography-mass spectrometry:
Qualitative analysis of the botanical root extracts and commercial devil's claw extracts was conducted using Ultra-high Performance Liquid Chromatography (UPLC). Chromatographic separation was carried out with a Dionex Ultimate 3000 HPLC system using a mobile phase gradient of 0.1% formic acid in 5% acetonitrile (solvent A) and 0.1% formic acid in acetonitrile (solvent B) on a C 18 column. Solvent A was initially 100% and Solvent B increased to 60% over a 30 min linear gradient, with a 60 min total run time. The injection volume was 5 μL for all samples. Analysis of samples was performed using high resolution Bruker Daltonics maXis Quadrupole Time-of-Flight (Q-TOF) mass spectrometer operated in electrospray ionization (ESI) mode. Samples were analyzed in both positive and negative ionization mode. The following source settings were used for both positive and negative ionization modes: nebulizer pressure: 1.5 bar; flow rate of drying gas (N 2 ): 8 L/min; drying gas temperature: 200°C; voltage between HV capillary and HV end-plate offset: 3000 V to −500 V; mass range was set from 80 to 1000 m/z; and the quadrupole ion energy was 4.0 eV.
